India Pharma Outlook Team | Thursday, 07 May 2026
India’s private healthcare crisis is raising serious concerns about the future of affordable treatment for millions of patients.
Several leading private hospital chains are reconsidering their participation in government-backed health schemes like Ayushman Bharat, CGHS, and ECHS, citing delayed payments, low reimbursement rates, and rising treatment costs.
The private healthcare crisis has also triggered fears that patients depending on cashless treatment may soon face fewer hospital options, longer waiting periods, and higher out-of-pocket expenses.
The issue is no longer limited to boardrooms and policy meetings. It is beginning to affect how hospitals manage admissions under public healthcare schemes across India.
Also Read: New Dynamics of Drug Distribution, Free Medicine Schemes in India
Private hospitals argue that reimbursement packages under government programs often fail to match the real cost of treatment. At the same time, hospitals are dealing with rising salaries for doctors and nurses, expensive imported medical equipment, inflation in medicines, and higher infrastructure costs.
According to industry estimates, government-backed schemes contribute nearly 20–25 percent of revenue for several large private hospital networks. However, consultancy firm Praxis Global Alliance expects that share to decline by 3–5 percent by FY27 as hospitals either reduce participation or limit admissions under government programs.
India’s Healthcare Dependence on Private Hospitals
Indicator | Data |
Share of outpatient care handled by private sector | ~70% |
Share of hospitalizations in private hospitals | ~60% |
Ayushman Bharat insurance cover | Rs 5 lakh per family |
Estimated PM-JAY beneficiaries | 55 crore+ |
Government-scheme contribution to some hospital revenues | 20–25% |
Expected decline in scheme revenue share by FY27 | 3–5% |
Some hospital groups have already started adjusting their approach toward government schemes.
Major healthcare providers including Max Healthcare, Narayana Health, Fortis Healthcare, and HealthCare Global Enterprises have publicly discussed financial pressure linked to government-backed treatment programs during earnings calls and investor discussions.
One of the strongest signals came from Max Healthcare, which reportedly said its participation in CGHS resulted in a revenue impact of nearly Rs 200 crore due to medicine discounts and low reimbursement structures. Hospital executives argue that some package rates are no longer financially sustainable, especially for specialized procedures and long-term treatments.
The pressure becomes more severe when delayed payments are added to the equation.
.jpg)
.jpg)
